AI assistant
MEMPHASYS LIMITED. — Capital/Financing Update 2017
Oct 9, 2017
65314_rns_2017-10-09_b5aff1f2-279d-4fe8-8c96-1b15acba7c44.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [222 x 64] intentionally omitted <==
ASX Release
R&D TAX REFUND
Sydney, Tuesday 10 October 2017
Memphasys Limited (ASX: MEM) is pleased to announce that it has received a Research and Development tax refund of $431,528.70.
Memphasys intends to apply these funds to further develop its ‘Felix’ device and for working capital purposes.
For further information please contact:
Alison Coutts Executive Chairman +61 2 8415 7300 [email protected]
About Memphasys:
Memphasys Limited (ASX: MEM) specialises in biological separations for high value commercial applications. The Company’s patented membrane processes in combination with electrophoresis, the application of an electrical potential difference across a fluid, enable the separation of high value substances or contaminants from the fluid in which they are contained.
The main application of the technology is the separation of the most viable sperm cells for artificial reproduction, most particularly for human IVF.
Postal Address Contact Details E [email protected] P.O. Box 2202 P +612 8415 7300 W memphasys.com Homebush West NSW 2140 F +612 8415 7399 ABN 33 120 047 556
Memphasys Limited 30-32 Richmond Road Homebush West NSW 2140